Reclassification of Active Products without Intended Medical Purpose in the European Union
The Commission published the Implementing Regulation (EU) 2022/2347, laying down rules for the reclassification of several active products without an intended medical purpose mentioned in MDR annex XVI. 

Active devices are classified according to MDR by the classification rules 9, 10, 11, 12 and 13. However, the rules 9 and 10 are applicable only to devices with an intended medical purpose and cannot be applied to active products without a medical purpose, specified in MDR annex XVI. Therefore, such products were classified as class I (according with rule 13) and had to demonstrate conformity with relatively less requirements than analogous devices with a medical purpose. 

Certain Member States requested the reclassification of several active products without an intended medical purpose to ensure an appropriate conformity assessment consistent with their inherent risks. 

Implementing Regulation (EU) 2022/2347 

On 2 December 2022, the Commission published the Implementing Regulation (EU) 2022/2347 in the Official Journal of the European Union, laying down rules for the reclassification of these products.  

The following groups of active products without an intended medical purpose listed in MDR Annex XVI are reclassified as follows:  

Section of annex XVI Product Previous classification Updated classification 
Section 4 Equipment intended to be used to reduce, remove or destroy adipose tissue.  Ex.: Equipment for liposuction, radiofrequency lipolysis, ultrasound lipolysis, cryolipolyisis, laser lipolysis, infrared and electrical stimulation lipolysis, acoustic shockwave therapy or lipoplasty Class I Class IIb 
Section 5 Equipment emitting high intensity electromagnetic radiation intended for hair removal.  Ex.: Lasers and intense pulsed light equipment Class I Class IIa 
Section 5 Equipment emitting high intensity electromagnetic radiation intended for skin treatment, skin resurfacing, scar removal, tattoo removal, or for treatment of nevi flammei, haemangioma, telangiectasia and pigmented skin areas.  Ex.: Lasers and intense pulsed light equipment Class I Class IIb 
Section 6 Equipment intended for brain stimulation that apply electrical currents or magnetic or electromagnetic fields that penetrate the cranium to modify neuronal activity in the brain.  Ex.: Equipment for transcranial magnetic stimulation or transcranial electric stimulation Class I Class III 

The Implementing Regulation (EU) 2022/2347 enters into force on 22 December 2022, is binding in its entirety and directly applicable in all Member States. 

For more information feel free to contact us at info@criticalcatalyst.com.

References:

Implementing Regulation (EU) 2022/2347

further
reading

medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »
medical devices

EUDAMED – harmonized practices and alternative solutions for IVDR until the database is fully functional

EUDAMED is one of the key aspects of the new rules on in vitro diagnostic medical devices – Regulation (EU) 2017/746. However, it is only expected to achieve full functionality by the second quarter of 2024. Until then, how is the information submitted and/or exchanged between manufacturers, notified bodies and competent authorities?

Read More »
medical devices

EUDAMED – update on timelines

EUDAMED is one of the key aspects of the new rules on medical devices (Regulation (EU) 2017/745) and in vitro diagnostic medical devices (Regulation (EU) 2017/746), and it is expected to achieve full functionality by the second quarter of 2024.

Read More »
cosmetic products

UK OPSS call for data on six cosmetic ingredients

On 14 July 2022, the Office for Product Safety and Standards (OPSS – the UK regulator for cosmetic products) issued a call for data on the safety of the following six cosmetic ingredients to investigate any suspected endocrine disrupting properties. 

Read More »